Prothena Corporation Plc (PRTA) 30.55 $PRTA
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Why Prothena Corporation PLC Shares Leaped Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Prothena , a clinical-stage...
Pipeline Progress at Prothena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 11:00AM CDT
Prothena Corporation (PRTA) has initiated a randomized, double-blind, placebo-controlled phase I trial on its monoclonal antibody candidate, PRX002.
First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's Disease
Thomson Reuters ONE - Tue Apr 08, 3:06PM CDT
- Entering clinic triggers $15 million milestone payment from Roche
3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.
Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:57AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rise over 27% on the day.
Why Prothena, Galena Biopharma, and Horizon Pharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 4:15PM CDT
Janet Yellen's first chaired Federal Open Market Committee meeting was certainly a memorable one, with the broad-based S&P 500 hiccuping and heading lower after the FOMC announced its latest policy decisions. According to Yellen, the...
Why Prothena (PRTA) Hit an All-Time High Today
at The Street - Wed Mar 19, 1:50PM CDT
Prothena (PRTA) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1....
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis
Thomson Reuters ONE - Tue Mar 18, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Increased Earnings Estimates Seen for Prothena Corporation (PRTA): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 7:46AM CDT
Prothena Corporation's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
Prothena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update
GlobeNewswire - Fri Mar 07, 2:59AM CST
Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on research and development.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Prothena Announces Appointment of Chief Business Officer
Thomson Reuters ONE - Mon Mar 03, 3:05PM CST
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena's demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena's previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease and other related synucleinopathies.
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Why Prothena Corporation PLC Shares Leaped Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Prothena , a clinical-stage...
Pipeline Progress at Prothena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 11:00AM CDT
Prothena Corporation (PRTA) has initiated a randomized, double-blind, placebo-controlled phase I trial on its monoclonal antibody candidate, PRX002.
First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's Disease
Thomson Reuters ONE - Tue Apr 08, 3:06PM CDT
- Entering clinic triggers $15 million milestone payment from Roche
3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.
Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:57AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rise over 27% on the day.
Why Prothena, Galena Biopharma, and Horizon Pharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 4:15PM CDT
Janet Yellen's first chaired Federal Open Market Committee meeting was certainly a memorable one, with the broad-based S&P 500 hiccuping and heading lower after the FOMC announced its latest policy decisions. According to Yellen, the...
Why Prothena (PRTA) Hit an All-Time High Today
at The Street - Wed Mar 19, 1:50PM CDT
Prothena (PRTA) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1....
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis
Thomson Reuters ONE - Tue Mar 18, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Increased Earnings Estimates Seen for Prothena Corporation (PRTA): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 7:46AM CDT
Prothena Corporation's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
Prothena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update
GlobeNewswire - Fri Mar 07, 2:59AM CST
Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on research and development. Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Prothena Announces Appointment of Chief Business Officer
Thomson Reuters ONE - Mon Mar 03, 3:05PM CST
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena's demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena's previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease and other related synucleinopathies. 
